Jul 29, 2020
Alkermes plc Reports Second Quarter 2020 Financial Results and Issues 2020 Financial Expectations
Jul 27, 2020
New Harris Poll Survey Offers Insights into Potential of Telepsychiatry During and After the COVID-19 Pandemic
Jul 22, 2020
Alkermes to Host Conference Call to Discuss Second Quarter 2020 Financial Results
Jun 29, 2020
Alkermes Announces Launch of 3rd Annual Alkermes Pathways Research Awards® Program
Jun 24, 2020
Alkermes Awards COVID-19 Relief Fund Grants to 10 Innovative Programs Designed to Address Challenges for Patient Communities
Jun 22, 2020
New Preclinical Data on ALKS 4230 in Combination With Lucitanib to be Presented at 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II
Jun 04, 2020
Alkermes to Take Part in 41st Annual Goldman Sachs Global Healthcare Conference
May 27, 2020
Alkermes Highlights New Data From Schizophrenia Portfolio at the American Society of Clinical Psychopharmacology 2020 Annual Meeting
May 20, 2020
Journal of Clinical Psychiatry Publishes Data from Alkermes' ALPINE Study in Patients With Schizophrenia
May 14, 2020
Alkermes Presents New Data From Schizophrenia Portfolio at Virtual 2020 Congress of the Schizophrenia International Research Society
May 11, 2020
Alkermes Announces Expansion of Patient Services and Provider Network to Support Uninterrupted Access to ARISTADA® and VIVITROL® During COVID-19 Crisis
May 06, 2020
Alkermes Announces Upcoming Presentation at the Bank of America Securities Virtual Health Care Conference
May 04, 2020
Alkermes Launches COVID-19 Relief Fund to Support Innovative Programs Helping Vulnerable Patient Communities
Apr 29, 2020
Alkermes Plc Reports First Quarter 2020 Financial Results and Provides COVID-19 Related Business Update
Apr 22, 2020
Alkermes to Host Conference Call to Discuss First Quarter 2020 Financial Results
Apr 22, 2020
Alkermes Announces Publication of Preclinical Data for ALKS 4230 in the Journal for ImmunoTherapy of Cancer
Mar 04, 2020
Journal of Clinical Psychiatry Publishes Data from Alkermes' Phase 3 ENLIGHTEN-1 Efficacy Study of ALKS 3831 in Patients With Schizophrenia
Feb 24, 2020
Alkermes' Corporate Presentation to be Webcast at the Cowen and Company 40th Annual Health Care Conference
Feb 13, 2020
Alkermes Plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2019 and Provides Financial Expectations for 2020
Feb 06, 2020
Alkermes to Host Conference Call to Discuss Fourth Quarter and Year-End 2019 Financial Results